Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Eluxadoline (Viberzi) is used for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. It significantly improves IBS global symptoms and bowel movement frequency, showing better outcomes in improving these symptoms and abdominal pain compared to other drugs.
• The safety and effectiveness of Viberzi for treating IBS-D among adults were assessed in three systematic reviews/meta-analyses.
• Nocebo effects can significantly impact adverse event reporting in IBS trials, as indicated by high adverse events reported even within placebo groups, but this does not directly provide data on Viberzi's side effect profile.
• Compared to other opioid receptor modulators used for treating IBS-D, eluxadoline has a low rate of constipation development, which suggests it may have a preferable safety profile regarding this specific side effect.
• All reviewed drugs, including Viberzi, were found superior to placebo; however, alosetron ranked highest for efficacy, while rifaximin ranked highest for safety, indicating that eluxadoline might not be the safest or most effective option available.
• Detailed insights into population types and subgroup considerations beyond broad categorization into IBS-D are unavailable, hence no specific analyses comparing Viberzi's performance across different patient demographics or conditions could be made.